Gilead and Vir partner on three solid-tumor cancer therapies

Gilead Sciences and Vir Biotechnology agreed on a collaboration to discover and develop three dual-masked T-cell engager candidates for solid tumors. Vir will conduct discovery, design and optimization using its PRO-XTEN masking and dAIsY AI platforms, while Gilead will hold exclusive rights to nominate and advance candidates and lead development, manufacturing and commercialization. The reported terms include $90m upfront, up to $45m in near-term preclinical milestones and up to $1.74bn in later development, regulatory and commercial milestones.

The agreement gives Vir potential non-dilutive and equity-linked funding plus access to Gilead’s development and commercial infrastructure, while giving Gilead rights to a pipeline of solid-tumor immunotherapies. The candidates remain experimental, so the future milestone payments depend on development and commercialization progress.

  • 1The collaboration covers three novel PRO-XTEN dual-masked T-cell engager development candidates aimed at selected solid-tumor-associated antigens.
  • 2Gilead will pay $90m upfront, with up to $45m in potential near-term preclinical milestones and up to $1.74bn in further development, regulatory and commercial milestones.
  • 3Vir will handle discovery, design and optimization, while Gilead will nominate and advance candidates and oversee development, manufacturing and potential commercialization.
  • 4One report described the potential value of the agreement as $1.88 billion.
  • 5Vir’s PRO-XTEN technology is designed to keep T-cell engagers inactive until they reach the tumor microenvironment.
  • Reports differ on the upfront consideration: some state $90m, while others report up to $135M, so the final upfront amount and its components are not consistent across the materials.
  • Reports also differ on the cash portion of the upfront payment, with one citing $65m and another citing $90 million.

Sources